Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–7 of 7 results
Advanced filters: Author: Gavin Churchyard Clear advanced filters

  • Stratifying tuberculosis (TB) disease into minimal, moderate or severe disease may allow treatment duration to be tailored to disease severity. Minimal poor adherence is associated with poor treatment outcomes.

    • Gavin J. Churchyard
    News & Views
    Nature Medicine
    Volume: 24, P: 1639-1641

  • Bauer et al. analyze blood-based immune and transcriptomic markers in tuberculosis patients to identify treatment failure and recurrence. They find that specific markers reliably detect microbiological non-conversion during treatment and recurrence after therapy, providing a sputum-independent tool for patient monitoring.

    • Bernadette Bauer
    • Mohamed I. M. Ahmed
    • Knut Lönnroth
    ResearchOpen Access
    Communications Medicine
    Volume: 6, P: 1-13

  • The treatment of tuberculosis is based on combinations of drugs that directly targetMycobacterium tuberculosis. A new global initiative is now focusing on a complementary approach of developing adjunct host-directed therapies.

    • Alimuddin Zumla
    • Jeremiah Chakaya
    • Markus Maeurer
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 14, P: 511-512

  • Resisters are individuals who show resistance to infection despite long-term, high exposure to Mycobacterium tuberculosis. In this Review, Simmons and colleagues discuss potential mechanisms underlying this resistance, such as those mediated by macrophages, T cells and B cells, and how an understanding of these mechanisms might aid in the development of therapies for tuberculosis.

    • Jason D. Simmons
    • Catherine M. Stein
    • Thomas R. Hawn
    Reviews
    Nature Reviews Immunology
    Volume: 18, P: 575-589

  • Mendelsohn et al. evaluated in a prospective multicentre validation study whether host-blood transcriptomic tuberculosis (TB) signatures could be used to find active cases of TB. Whilst most of the signatures met WHO Target Product Profile criteria for a triage test to diagnose symptomatic TB; most signatures did not meet the criteria for asymptomatic TB.

    • Simon C. Mendelsohn
    • Stanley Kimbung Mbandi
    • Thomas J. Scriba
    ResearchOpen Access
    Communications Medicine
    Volume: 2, P: 1-13